

(12) UK Patent Application (19) GB (11) 2 148 299 A

(43) Application published 30 May 1985

(21) Application No 8323428	(51) INT CL ⁴ C07K 15/00 A61K 39/395 // 39/44
(22) Date of filing 1 Sep 1983	(52) Domestic classification C3H 514 526 530 HX2 A5B 180 216 21Y 29X 29Y 30X 30Y 311 313 315 31X 31Y 320 325 32Y H U1S 1330 1335 2419 A5B C3H
(71) Applicant Hybritech Incorporated (USA-California), 11085 Torreyana Road, San Diego, California 92121, United States of America	(56) Documents cited GB A 2098219 GB 1564666 GB A 2090837 GB 1509707 GB A 2034324 EP A2 0044167
(72) Inventors James M. Frincke, Barbara W. Unger, Karen G. Burnett, Evan M. Hersh, Michael Gordon Rosenblum, Jordan Udell Guttermann	(58) Field of search C3H
(74) Agent and/or Address for Service J. A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5EU	

(54) Antibody compositions of therapeutic agents having an extended serum half-life

(57) A complex of a therapeutic agent e.g. alpha-interferon with a monoclonal antibody complexes with the therapeutic agent without impairing its therapeutic activity. The serum half-life of interferon administered as the complex is substantially increased when compared to that of the interferon administered alone.

GB 2 148 299 A

SPECIFICATION

Antibody compositions of therapeutic agents having an extended serum half-life

5

Field of the invention

This invention relates to therapeutically active agents and the treatment of disease therewith. In another aspect, it relates to antibody complexes of a therapeutically active agent. In a more specific aspect it relates to complexes of a monoclonal antibody and a therapeutically active agent and their use in the treatment of disease.

15 *Background*

It is almost a trite observation to note that the use of a broad spectrum of drugs to treat human and other mammalian disease is routine medicinal and veterinary practice. Therapeutically active agents, however, often suffer from a number of shortcomings which limit, or at least complicate their use. A particular problem is that, after administration to the patient, a drug may be so rapidly cleared from the body by metabolic or other pathways or otherwise biologically inactivated so that only a relatively small percentage of the drug administered actually has a therapeutic effect. To compensate for this problem, it is common practice to increase the dosage of the drug and/or to administer it at intervals which are close enough together so that the therapeutically effective concentration of the drug in the patient is maintained for a period sufficient to achieve the desired result.

These procedures are useful but have their own limitations. Increasing the dosage may be limited, for example, in the case of intramuscular administration, by the bolus which can be tolerated. Many drugs have toxic side effects which may limit the dosage which can be safely administered. In some cases, promising drugs cannot be used because side reactions are so severe that an effective therapeutic dose cannot be safely administered. The need to administer multiple small doses of a drug or to use continuous infusion techniques increases the cost of treatment and the burden on hospital personnel and, of course, adds to the patient's discomfort.

Accordingly, there exists a need for means by which the therapeutically active concentration of a drug, after administration, is maintained for a longer time.

Summary of the invention

It is the normal and expected function of antibodies to complex with foreign substances to more rapidly clear them from the body. We, however, have unexpectedly found that the serum or plasma half-life of a therapeutically active agent can be extended by forming a complex of the agent with a selected antibody, preferably a monoclonal antibody, which binds to the agent at a site which does not substantially impair its therapeutic activity and which extends the serum half-life of the agent. Thus, as used herein, the term "antibody" means a monoclonal antibody or polyclonal anti-

bodies unless otherwise specified or required by the context. According to our invention, the complex of the therapeutically active agent and the antibody may be formed *in vitro* and then

70 administered. Alternatively, the agent and antibody may be administered at the same time. In yet another alternative, the antibody may be administered first, and after an interval during which its distribution in the patient approaches equilibrium, the therapeutically active agent can be administered.

By selecting the proper antibody for forming the antibody: drug complex, the serum half-life and, thus, the effective concentration of the therapeutically active agent, can be maintained *in vivo* for a longer interval. While monoclonal antibodies are preferred for use in the invention, it is also within the scope of the invention to use polyclonal antibodies against the therapeutically active agent which complex with the therapeutically active agent without materially impairing its therapeutic activity.

Accordingly, it is an object of the present invention to provide means by which the serum half-life of a therapeutically active agent is extended.

Another object of the invention is to provide compositions which increase the effective lifetime of a therapeutic agent *in vivo* after administration to a patient.

95

Detailed description of the invention

As indicated above, the present invention, in one embodiment, is a complex between a therapeutically active agent with a monoclonal antibody selected to bind the therapeutic agent at a site which does not materially impair its therapeutic activity but which forms a complex with the agent to confer upon the agent a serum half-life longer than that of the therapeutic agent alone. Alternatively, the invention comprises a similar complex of therapeutic agent with polyclonal antibodies selected to bind the antibody without materially impairing its therapeutic activity and which form a complex having an extended serum half-life.

110 In another embodiment, the invention is a process involving the administration to a host of a complex comprising the therapeutic agent and either a monoclonal antibody or polyclonal antibodies having the properties noted above. The process of the present invention also includes either simultaneous administration of the therapeutic agent and a suitable antibody preparation followed by administration of the therapeutic agent after the antibody has had an opportunity to distribute itself throughout the host.

120 The therapeutic agents useful in the invention are those which are or can be made immunogenic, i.e., those for which an immune response can be obtained either directly or, in the case of a hapten, by binding the agent to a molecule which is immunogenic. Monoclonal antibodies against the therapeutic agent can be obtained by methods which are now well known to the art and which need not be described in detail. These methods generally involve immunization of a mouse or other animal

130

species, usually mammalian or avian, with the immunogen. After an immune response is generated, spleen cells of the immunized mouse are fused with cells of an established lymphoid tumor line

5 using known techniques to form hybridomas which produce monoclonal antibodies. Clones of hybridomas are screened to select those which are producing monoclonal antibodies that are specific for the antigen of choice, in this case the therapeutic agent. Monoclonal antibodies having the desired specificity are further screened to select those that form an antibody: agent complex in which the agent retains all, or substantially all, of its therapeutic activity. These complexes are further
10 screened to select those which have an extended serum half-life. In certain circumstances, it can be beneficial to use a mixture of two or more monoclonal antibodies. In some circumstances it may also be desirable to use a stoichiometric excess of
20 antibody.

Polyclonal antibodies useful in the invention are obtained by well known techniques as well. These include stimulating an immune response against the therapeutic agent, or fragment thereof, in a
25 suitable animal host such as a rabbit or other mammal. Chickens and other avian species can also be used. Serum taken from the host is subjected to affinity purification to isolate polyclonal antibodies against the therapeutic agent. These antibodies are subsequently fractionated, if necessary, to isolate a subpopulation which complexes with the therapeutic agent without materially impairing its desirable activity.

Particularly preferred for use in the invention are
35 human antibodies against the therapeutic agent produced by hybridomas which, for example, are the product of fusion of a human B-lymphocyte with an established mammalian lymphoid line, e.g., a human or mouse myeloma line.

40 As used herein, the term antibody includes fragments thereof such as Fab, Fab' and Fab'2 or mixtures thereof and including mixtures with whole antibody. Such fractions may be less immunogenic in some patients and may also better allow better
45 penetration of the agent to the target site.

In certain applications, the monoclonal antibody is preferably a hybrid antibody having a dual specificity, one against the therapeutically active agent and the other against an other antigen, for example, an antigen associated with the disease which it is desired to treat with the agent. Among these
50 may be mentioned tumor associated antigens such as carcinoembryonic antigen (CEA), prostatic acid phosphatase (PAP), ferritin and prostate specific antigen (PSA). In such cases, the other specificity
55 could be selected to bind with an agent which has anti-tumor activity. For example, the second specificity could be against a toxin such as ricin or an interferon. Processes for obtaining such hybrids
60 are disclosed in the pending patent application of J. Martinis et al., Serial No. 367,784, filed April 12, 1983, assigned to Hybritech Inc., an assignee of this application, the disclosure of which is incorporated by reference.

65 Among the therapeutic agents which are useful

in the invention may be mentioned drugs such as vincristine, genomycin, mitomycin C, and prostacyline; toxins such as abrin and ricin; and biological proteins such as the interferons (alpha, beta and gamma), the interleukins, hormones such as insulin, plasminogen activators such as urokinase, streptokinase and tissue plasminogen activator, growth factors such as nerve growth factors, and platelet activating factor. Particularly useful are
70 complexes of a monoclonal antibody and one of the interferons, for example, alpha-interferon. As used herein, the term "interferon" is used to include those agents having the characteristics attributed to interferons as described in *Interferon: An Overview*, Ion Gresser, Ed., 4 (1982), p. 4, which is incorporated herein by reference. It is also used to mean an interferon as it occurs naturally or a synthetic modification thereof. In particular, it includes an interferon made by recombinant DNA
75 technology which is identical to a naturally occurring interferon or which differs therefrom by one or more of the following:

1. a difference in amino acid sequence;
2. a difference in chain folding;
3. a difference in carbohydrate substitution.

The utility of the present invention is shown by the experiments described below with alpha-interferon. In that regard, alpha-interferon, a multi-species interferon, has been shown to have a
95 therapeutic effect in the treatment of certain malignant tumors including breast cancer, multiple myeloma and malignant lymphoma. However, it has been shown to rapidly clear from the plasma of man and animals during clinical trials. This has
100 been compensated for by giving a high dose intramuscularly. However, the maximum dose is limited because of high-dose toxic side effects. Also, the high doses used are very expensive and may elicit an immune response in a substantial number of patients treated.

The following Example is given to illustrate the invention.

1. Preparation of anti- α -interferon monoclonal antibodies:

110 Balb/c mice were immunized with partially purified leukocyte interferon. Spleen cells from immunized mice were fused with a myeloma line (either the NS-1 or SP2/0 lines) to produce hybridomas. The hybridomas were screened to select those reactive with ¹²⁵I-labeled interferon in a radioimmunoassay wherein the immune complexes were removed by horse anti-mouse IgG bound to sepharose beads. Interferon used in immunization and screening were from the same source. Antibodies were selected for positive reactivity with interferon. Hybridomas producing the selected
120 antibodies were cloned by limiting dilution to ensure homogeneity of the cell population.

2. Testing for reactivity of an antibody: interferon immune complex in the anti-viral protection assay

125 Approximately 40 anti-alpha interferon monoclonal antibodies were employed to make interferon: antibody immune complexes which were tested for retention of anti-viral activity using the

standard method described, for example, in Rubinstein, et al., *J. Virology*, 37, 755 (1981). The first step in this procedure was formation of the immune complex by the addition of ascitic fluid to

the anti-viral protection assay mixture which was monitored for inhibition of interferon activity. Ten of the forty antibodies were selected for further investigation because they did not inhibit the viral protection properties of the interferon in this assay.

These antibodies were then further concentrated with sodium sulfate and re-tested. In each case, non-inhibition of anti-viral activity was verified. To demonstrate whether complexes of interferon with these antibodies were actually formed, the reaction

mixtures were absorbed with solid phase sepharose bound sheep anti-mouse IgG to remove the antibody and complexed interferon. The supernatant from the sepharose absorptions were then tested in the standard antiviral protection assay. In

the case of one particular antibody, designated IFG 252.2 by us, the antiviral protection was almost completely removed from the supernatant during the absorption. Controls were performed to ensure this phenomena was not due to non-specific absorption during the sepharose absorption step. These data demonstrate that this antibody binds efficiently and avidly to interferon without inhibiting its antiviral activity.

Another known biological property of alpha interferon is its inhibition of cellular proliferation. In an assay system using DAUDI cells, retention of anti-proliferative activity was demonstrated for alpha interferon in the presence of the IFG 252.2 antibody. The anti-proliferative activity was almost

totally removed using sheep anti-mouse sepharose beads to absorb interferon: IFG 252.2 immune complexes from the reaction mixture. These data demonstrate that IFG 252.2 also binds alpha interferon without affecting its anti-proliferative activity.

3. Administration of alpha-interferon: IFG 252.2 complex to laboratory rats

A Fisher rat (250-260 g) was lightly anesthetized with sodium thiopental. A plastic canula was then surgically inserted into the femoral vein and another canula into the femoral artery of the other leg. A bolus dose of alpha-interferon (Cione A of Goeddel et al., *Nature*, 290, 20-26 (1981), 7600 units total in 0.5 ml PBS) was administered over 2 seconds into the venous catheter. Blood samples (0.5 ml) were withdrawn at various times from the arterial catheter. After each blood withdrawal, 0.5 ml of PBS were injected via the venous catheter. The samples were centrifuged, the plasma decanted and analyzed for interferon anti-viral activity by standard methods. In a second rat, the same amount of interferon was preincubated with IFG 252.2 (38 microgram microliter 190 micrograms antibody) and then administered through the venous catheter. Blood samples were taken and analyzed in the same way as for the first. The result of these experiments were then plotted and subjected to nonlinear regression analysis.

These results indicate that the activity of alpha-interferon in the rat without added anti-interferon

phase has a 6.8 minutes half-life with a two log reduction of interferon activity in the plasma at 30 minutes. The volume of distribution is 20.8 ml. At 30 minutes a beta component to the plasma disappearance curve is identified with a 30 minute half-life. At two hours essentially all of the interferon activity has been lost from the plasma. In contrast, when the IFG 252.2 antibody is utilized as an adjuvant, a single phase disappearance of activity from plasma is observed. The half-life of this activity loss is 84 minutes, twelve times longer than that observed for alpha-interferon itself, with a volume of distribution of 19.2 ml, essentially equivalent to that observed for alpha-interferon without added antibody.

The foregoing experiments demonstrate that, by proper selection of an antibody, the serum half-life of a therapeutically active agent can be usefully extended without significant impairment of therapeutic activity.

Those skilled in the art will recognize that the invention, therefore, has application in veterinary medicine and for human health care. In that connection, it is within the scope of the invention to combine the therapeutic agent and/or the antibody or the antibody complex with the agent with other components such as a suitable vehicle. The foregoing description of the invention is exemplary only and modifications thereof may be made without departure from the scope of the invention which is to be limited only by the appended claims.

CLAIMS

1. A composition comprising a complex of a therapeutically active agent and an antibody selected to bind said agent at a site which does not substantially impair its therapeutic activity and which extends the serum half-life of the therapeutically active agent.

2. A composition according to Claim 1 wherein the antibody is a monoclonal antibody.

3. A composition according to Claim 1 wherein the antibody comprises a population of polyclonal antibodies.

4. A composition according to Claim 1 wherein the antibody is a hybrid monoclonal antibody having a dual specificity one of which is against the therapeutically active agent and the other against a disease associated antigen.

5. A composition according to Claim 4 wherein one specificity of the hybrid antibody is directed against a tumor associated antigen and the other against an agent having anti-tumor activity.

6. A composition according to Claim 5 wherein the tumor associated antigen is selected from CEA, PAP, PSA or ferritin.

7. A composition according to Claim 5 or 6 wherein the second specificity is directed against an interferon.

8. A composition according to any one of the preceding Claims wherein the antibody comprises an antibody fragment of Fab, Fab' or Fab'2

9. A composition according to any one of the preceding Claims wherein the therapeutically ac-

10. A composition according to any one of the preceding Claims wherein the therapeutically active agent is an interferon.

11. A composition according to Claim 10 wherein the interferon is alpha, beta or gamma interferon.

12. A composition according to any one of the 10 preceding Claims further comprising a pharmaceutical vehicle.

13. A composition according to Claim 1 substantially as hereinbefore described with reference to any one of the Examples.

15 14. A process for the production of a composition as defined in any one of the preceding Claims wherein the antibody and agent are combined *in vitro*.

15. A process for the production of a composition as defined in any one of the preceding Claims wherein the antibody and agent are combined *in vivo*.